IBS is a widespread condition that affects the digestive system, which causes the symptoms diarrhea, abdominal pain and flatulence. The estimated global prevalence is 11% and has been increasing significantly over the last years.¹

The efficacy of our strain MIMBb75 for the treatment of IBS is supported by two gold standard studies.^2,3 The second clinical trial is one of the largest OTC studies and was recently published in the journal "The Lancet Gastroenterology & Hepatology".²

Our heat-inactivated strain not only retains its significant efficacy in treating these symptoms, it supports overall health and well-being. Adding to that, it is unique in terms of stability and processing capabilities - making it ideal for further processing.

¹Prevalence rose by +30% across all age groups with 1 million newly diagnosed people per year in Germany.

²Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020 Jul;5(7):658-666. doi: 10.1016/S2468-1253(20)30056-X.

³Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life—a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011 May;33(10):1123-32. doi: 10.1111/j.1365-2036.2011.04633.x.